ADAM19

Across TCGA pan-cancer cohorts, ADAM19 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ADAM19 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAM19 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAM19 expression acts as an unfavorable survival marker.

PDAC are the cancer types where ADAM19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.214	0.509	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ADAM19–PDAC (DFS)

Open the PDAC breakdown →